Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.

Clinical transplantation - 1 Jan 2000

Chen Si-Yang, Li Jia-Li, Meng Fan-Hang, Wang Xue-Ding, Liu Tao, Li Jun, Liu Long-Shan, Fu Qian, Huang Min, Wang Chang-Xi

Abstract excerpt

We investigated how cytochrome P450 (CYP) 3A5 polymorphism affects pharmacokinetics of tacrolimus and its interaction with diltiazem in Chinese kidney transplant recipients. Sixty-two CYP3A5 expressers and 58 non-expressers were, respectively, randomized to receive diltiazem supplement or not. Their pharmacokinetic profiles were acquired on 14th day, sixth month, and 18th month post-transplant and compared among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Immunosuppressive Agents

Share to Kidney Diseases

Share to Kidney Transplantation

Share to Tacrolimus

Share to Tissue Distribution

Source

Identifiers

PMID: 23432535
DOI: 10.1111/ctr.12101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.PMID 23432535Read ↗

Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis.Semantic proximity Read ↗

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.Semantic proximity Read ↗

Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.Semantic proximity Read ↗

Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.Semantic proximity Read ↗

Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.Semantic proximity Read ↗

Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients.Semantic proximity Read ↗

Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.Semantic proximity Read ↗

Multicenter Prospective Trial Evaluating the Utility of CYP3A5 Genotype in Determining Optimal Initial Dosage of Tacrolimus in Chinese Renal Transplant RecipientsSemantic proximity Read ↗

Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients.Semantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.